MedTrace Logo

Molecular Biomarkers Predicting Early Development of Endometrial Carcinoma

NCT05273099 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 8

Last updated 2022-04-12

No results posted yet for this study

Summary

Endometrial carcinoma represents the most common gynaecological cancer and the sixth most frequent cancer among women worldwide. The 5-year survival of patients with stage I endometrial carcinoma is 75%-88% versus 50% for stage III or 15% for stage IV disease. Therefore, early detection could improve survival rates. Specifically, in the most prevalent, type 1 endometrial cancer develops from hyperplastic endometrium. The aim of the study was to evaluate the utility of cancer gene mutations from endometrial biopsies towards predicting synchronous or metachronous development of malignant lesions. The aim of the study was to evaluate whether endometrial biopsies could already carry mutations in cancer genes useful for predicting or anticipating subsequent cancer development

Conditions

  • Cancer of Endometrium

Sponsors & Collaborators

  • Università degli Studi di Ferrara

    lead OTHER

Principal Investigators

  • Gennaro Scutiero, MD · Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara, Italy

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-01
Primary Completion
2023-03-31
Completion
2023-12-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05273099 on ClinicalTrials.gov